• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » CenterWatch Monthly June 2010

CenterWatch Monthly June 2010

June 3, 2010
CenterWatch Staff

i3 Research, PPD, Kendle, Covance Rated Top CROs in Europe in 2010

 i3 Research, Kendle and Covance remain top-rated CROs in the 2010 CenterWatch European Site Survey. i3 Research outpaced other CROs this year to achieve a top CRO rating in overall relationship quality with investigative sites. PPD made a significant improvement compared with the 2008 survey and earned a second-place distinction in the 2010 survey, exhibiting strengths in organization/preparation, responsiveness to inquiries and demonstrating a supportive culture.

Vaccine Studies Growth Good for Sites, CROs

Vaccine sales are expected to double to $39 billion by 2013 as drug sponsors focus on vaccines as a growth area. Some vaccine-focused sites and CROs are reporting that vaccine studies have turned around their businesses after a difficult period. Sites that refine their processes in response to the demand for vaccine development work, particularly for studies that require enrolling a large number of participants during a short period of time, will have an edge up on the competition.

Eye On:  Brain Cancer

Although nearly 200,000 patients each year are diagnosed with brain cancer, only about 40,000 of these are primary brain tumors, and the rest are metastatic cancers arising from the breast, lung, colon, prostate or other distant organs. Among people under the age of 20 years, primary brain cancers are the leading cause of mortality from solid tumors. Peak age incidence of primary brain cancers is 45 to 65 years.

To read the full articles for this issue or for more information on these and other breaking stories, please click here for subscription information.

Upcoming Events

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing